Moga, Esther <br/><br/>
NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.  [electronic resource] 

 -  Experimental hematology  Jan 2008 
 - 69-77 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0301-472X 
<br/><br/><label>Standard No.: </label>10.1016/j.exphem.2007.08.012  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Adult<br/>Antibodies, Monoclonal--immunology<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antibody-Dependent Cell Cytotoxicity--drug effects<br/>Burkitt Lymphoma--pathology<br/>Cell Line, Tumor--drug effects<br/>Drug Synergism<br/>Humans<br/>Interferon-gamma--biosynthesis<br/>Interleukin-15--administration & dosage<br/>Killer Cells, Natural--drug effects<br/>Leukocytes, Mononuclear--drug effects<br/>Lymphocyte Activation--drug effects<br/>Oligodeoxyribonucleotides--administration & dosage<br/>Rituximab<br/>Toll-Like Receptor 9--agonists